We are live on ! Find out more
ACM

Atika Capital Management Portfolio holdings

AUM $796M
1-Year Est. Return 167.57%
This Fund
S&P 500
This Quarter Est. Return
+15.85%
1 Year Est. Return
+167.57%
3 Year Est. Return
+553.47%
5 Year Est. Return
+1,283.26%
10 Year Est. Return
+44,203.78%
AUM
$285M
AUM Growth
+$81.2M
Cap. Flow
+$62.5M
Cap. Flow %
21.89%
Top 10 Hldgs %
40.02%
Holding
95
New
33
Increased
14
Reduced
26
Closed
19

Top Buys

Rank Stock Value
1
AAL icon
American Airlines Group
AAL
+$5.63M
2
ALGN icon
Align Technology
ALGN
+$5.29M
3
TTWO icon
Take-Two Interactive
TTWO
+$5.13M
4
MDCO
Medicines Co
MDCO
+$5.08M
5
FWONK icon
Liberty Media Series C
FWONK
+$4.43M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$6.3M
2
INCY icon
Incyte
INCY
+$4.81M
3
AGN
Allergan plc
AGN
+$4.66M
4
GKOS icon
Glaukos
GKOS
+$3.02M
5
UAL icon
United Airlines
UAL
+$2.92M

Sector Composition

Rank Sector Weight
1 Healthcare 28.33%
2 Technology 16.3%
3 Communication Services 13.78%
4 Consumer Discretionary 5.9%
5 Materials 4.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
76
DELISTED
Zogenix, Inc.
ZGNX
$420K 0.15%
29,000
-38,000
-57% -$478K
ABBV icon
77
PUT
AbbVie
ABBV
$465B
– –
-30,000
Closed -$1.95M
ACAD icon
78
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-65,200
Closed -$2.24M
ALB icon
79
Albemarle
ALB
$13.4B
– –
-22,000
Closed -$2.32M
BMRN icon
80
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-5,100
Closed -$447K
BPMC
81
DELISTED
Blueprint Medicines
BPMC
– –
-24,000
Closed -$960K
GDX icon
82
VanEck Gold Miners ETF
GDX
$22.5B
– –
-120,000
Closed -$2.74M
INCY icon
83
Incyte
INCY
$25.8B
– –
-36,000
Closed -$4.81M
NXST icon
84
Nexstar Media Group
NXST
$6.01B
– –
-41,500
Closed -$2.91M
PCRX icon
85
Pacira BioSciences
PCRX
$1.04B
– –
-31,000
Closed -$1.41M
PTC icon
86
PTC
PTC
$15.3B
– –
-48,000
Closed -$2.52M
RAMP icon
87
LiveRamp
RAMP
$2.29B
– –
-98,700
Closed -$2.81M
RGLD icon
88
Royal Gold
RGLD
$16.6B
– –
-19,000
Closed -$1.33M
UAL icon
89
United Airlines
UAL
$38.8B
– –
-41,400
Closed -$2.92M
XBI icon
90
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-142,000
Closed -$9.84M
NVRO
91
DELISTED
NEVRO CORP.
NVRO
– –
-67,200
Closed -$6.3M
BMCH
92
DELISTED
BMC Stock Holdings, Inc
BMCH
– –
-107,000
Closed -$2.42M
AGN
93
DELISTED
Allergan plc
AGN
– –
-19,500
Closed -$4.66M
ARRY
94
DELISTED
Array Biopharma Inc
ARRY
– –
-175,000
Closed -$1.56M
IPXL
95
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-39,500
Closed -$499K
1 2 3
4

Similar funds

AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
RIM
Rovida Investment Management Grand Cayman, Cayman Islands $797M AUM 111.83% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
CAM
CenterStar Asset Management Chicago, Illinois $797M AUM 28.71% 1-Year Est. Return
Legacy Financial Group (Iowa)
Legacy Financial Group (Iowa) Des Moines, Iowa $795M AUM 12.87% 1-Year Est. Return
LSA
L & S Advisors Los Angeles, California $795M AUM 52.77% 1-Year Est. Return
GWA
Geometric Wealth Advisors Washington, District of Columbia $799M AUM 22.19% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

Atika Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Atika Capital Management held 95 positions worth $285M, up 40% from $204M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Atika Capital Management deployed $62.5M of net new capital in Q2 2017, opening 33 new positions and adding to 14 existing holdings. Its largest new stake was American Airlines Group: 121,000 shares worth $6.09M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 36% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Glaukos, an estimated $3.02M trimmed.

  • Atika Capital Management's largest Q2 2017 buy was American Airlines Group: 121,000 shares worth $6.09M.
  • Atika Capital Management added most to Align Technology in Q2 2017, an estimated $5.29M increase.
  • Atika Capital Management's biggest Q2 2017 reduction was Glaukos, cutting an estimated $3.02M.
  • Atika Capital Management fully exited NEVRO CORP. in Q2 2017, selling an estimated $6.3M.
  • Atika Capital Management's ten largest holdings make up 40% of its $285M portfolio in Q2 2017.
  • Atika Capital Management opened 33 new positions and closed 19 in Q2 2017.
  • Atika Capital Management's portfolio value rose 40% quarter-over-quarter to $285M.

Based on Atika Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.